Delgocitinib is under clinical development by Leo Pharma and currently in Phase II for Alopecia. According to GlobalData, Phase II drugs for Alopecia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Delgocitinib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Delgocitinib (Corectim) acts as anti-allergic agent. It is formulated as ointment for topical application. Corectim is indicated for the treatment of atopic dermatitis.
Delgocitinib (JTE-052) is under development for the treatment of autoimmune/allergic diseases like chronic hand eczema, dry eye disease including Sjogren’s syndrome, mild to moderate inverse psoriasis and frontal fibrosing alopecia (FFA). The drug candidate is administered through topical, oral, cutaneous and ophthalmic routes. It acts by targeting pan Janus kinase (JAK ). It was also under development for discoid lupus erythematosus and alopecia areata.
Leo Pharma overview
Leo Pharma, a subsidiary of LEO Foundation, is a drug manufacturing company. It discovers, develops, manufactures, and commercializes medicines for skin diseases and thrombosis. Its product portfolio spans pharmaceuticals for the treatment of diseases such as eczema, psoriasis, skin infections, actinic keratosis, non-melanoma skin cancer, and thrombosis. The company also manufactures and markets products for the treatment of bacterial infections, coagulation, cardiovascular, antibiotics, nutritional disorders, osteoporosis, and renal problems. Leo Pharma markets its products worldwide. The company has a presence in Europe, the Middle East, Africa, Asia, the Americas, and Oceania. Leo Pharma is headquartered in Ballerup, Denmark.
For a complete picture of Delgocitinib’s drug-specific PTSR and LoA scores, buy the report here.